Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20964)	5/17/1998 10:44:00 AM
From: Machaon	Respond to of 32384

From the FT article << Although many of them will not make the grade in the clinic, even cautious oncologists expect a few anti-angiogenic drugs to work well on people. They will then add to our growing armory of cancer treatments, in combination with other approaches. But none will come close to curing cancer on its own. >> Again, there will not just be "one" magic bullet. It's not a winner take all race for a cancer cure. It makes me feel more comfortable investing in cancer biotech companies. I guess we can compare cancer cures with heart cures. There are a mess of different ACE Inhibitors and Calcium Blockers, even though their effects are very similar. Another thing that makes me feel more comfortable, about my investment in LGND, is your enthusiasm about LGND. Your knowledge and understanding of LGND and their science, and your willingness to share your research efforts, with others, is much appreciated. Regards, Bob